Evidence map›Paper›PMID 17156422›Full record

ArticleBMC biotechnology2006

A simple vector system to improve performance and utilisation of recombinant antibodies.

Cecile D Martin, Gertrudis Rojas, Joanne N Mitchell, Karen J Vincent, Jiahua Wu, John McCafferty, Darren J Schofield

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Engineering Homogeneous Photoactive Antibody Fragments.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  12. Review
  13. Article
  14. Orally active bivalent ViScience · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Enhancing the detection ofBiotechnology reports (Amsterdam, Netherlands) · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Cecile D MartinAtlas of Protein Expression, Wellcome Trust Sanger Institute, Genome Campus, Morgan Building, Hinxton, Cambridgeshire, CB10 1HH, UK. cecile.d.martin@gsk.com <cecile.d.martin@gsk.com>
Gertrudis Rojas
Joanne N Mitchell
Karen J Vincent
Jiahua Wu
John McCafferty
Darren J Schofield
Wellcome Sanger Institute · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundIsolation of recombinant antibody fragments from antibody libraries is well established using technologies such as phage display. Phage display vectors are ideal for efficient display of antibody fragments on the surface of bacteriophage particles. However, they are often inefficient for expression of soluble antibody fragments, and sub-cloning of selected antibody populations into dedicated soluble antibody fragment expression vectors can enhance expression.

resultsWe have developed a simple vector system for expression, dimerisation and detection of recombinant antibody fragments in the form of single chain Fvs (scFvs). Expression is driven by the T7 RNA polymerase promoter in conjunction with the inducible lysogen strain BL21 (DE3). The system is compatible with a simple auto-induction culture system for scFv production. As an alternative to periplasmic expression, expression directly in the cytoplasm of a mutant strain with a more oxidising cytoplasmic environment (Origami 2 (DE3)) was investigated and found to be inferior to periplasmic expression in BL21 (DE3) cells. The effect on yield and binding activity of fusing scFvs to the N terminus of maltose binding protein (a solubility enhancing partner), bacterial alkaline phosphatase (a naturally dimeric enzymatic reporter molecule), or the addition of a free C-terminal cysteine was determined. Fusion of scFvs to the N-terminus of maltose binding protein increased scFv yield but binding activity of the scFv was compromised. In contrast, fusion to the N-terminus of bacterial alkaline phosphatase led to an improved performance. Alkaline phosphatase provides a convenient tag allowing direct enzymatic detection of scFv fusions within crude extracts without the need for secondary reagents. Alkaline phosphatase also drives dimerisation of the scFv leading to an improvement in performance compared to monovalent constructs. This is illustrated by ELISA, western blot and immunohistochemistry.

conclusionNine scFv expression vectors have been generated and tested. Three vectors showed utility for expression of functional scFv fragments. One vector, pSANG14-3F, produces scFv-alkaline phosphatase fusion molecules which offers a simple, convenient and sensitive way of determining the reactivity of recombinant antibody fragments in a variety of common assay systems.

Indexed as

Cloning, MolecularGenetic VectorsImmunoassayAlkaline PhosphataseBlotting, WesternDNA-Directed RNA PolymerasesEnzyme-Linked Immunosorbent AssayEscherichia coliImmunoglobulin Variable RegionImmunohistochemistryPeptide LibraryPromoter Regions, GeneticRecombinant Fusion ProteinsViral ProteinsAlkaline Phosphatasebacteriophage T7 RNA polymeraseDNA-Directed RNA PolymerasesImmunoglobulin Variable RegionPeptide LibraryRecombinant Fusion ProteinsViral Proteins

Identifiers

PMID17156422
PMCPMC1712229
OpenAlexW2113627832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.